{"id":"W4416808481","doi":"10.1016/j.jtho.2025.11.018","title":"Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Alberta Health Services","funders":"National Cancer Institute; National Institutes of Health; Eli Lilly and Company","keywords":"Pembrolizumab; KRAS; Immunotherapy; Adverse effect; PD-L1","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005702168,0.0004280611,0.001045467,0.0002677985,0.0002273464,0.0004438685,0.0002949732,0.0003778304,0.001037159],"category_scores_gemma":[0.0005675228,0.000195059,0.0005357788,0.000284573,0.0001996217,0.0002913181,0.0001721001,0.001117645,0.0002562677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005513867,"about_ca_system_score_gemma":0.0004529393,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005049548,"about_ca_topic_score_gemma":0.001721048,"domain_scores_codex":[0.9997961,0.00007670147,0.0000250149,0.00002943566,0.00003719022,0.00003562299],"domain_scores_gemma":[0.9997603,0.00005323096,0.00007418825,0.00001191963,0.00001529878,0.00008511989],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2644969,0.01497468,0.07321142,0.001280744,0.00217208,0.0008283668,0.0003914663,0.004663229,0.1002579,0.0001407207,0.003268908,0.5343137],"study_design_scores_gemma":[0.1276518,0.4408192,0.3788163,0.0002789859,0.002833328,0.003526999,0.0002024655,0.007897564,0.0266133,0.0002470227,0.0110228,0.00009027596],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939644,0.004412273,0.0001394609,0.0002105186,0.00001949251,0.000117054,0.0001657758,0.00003096278,0.0009400801],"genre_scores_gemma":[0.9980268,0.001079874,0.0002507977,0.0001088741,0.00002896042,0.0000577965,0.0002347134,0.000003907842,0.0002083715],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001045467,"threshold_uncertainty_score":0.004000604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009457525746142717,"score_gpt":0.3542840401924118,"score_spread":0.3448265144462691,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}